NASDAQ · STOCK
Abbott Laboratories
$93.93
52W $81.97 – $137.49
61/100
$218881.63T
26.1
0.61
Price History (6M)
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Growth Analyst: 4 consecutive earnings misses -- execution concerns. Overall recommendation: WATCH.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Bearish candlestick pattern(s) detected: Three Black Crows.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
61/100
Agreement
57%
Analysts
7
Conviction
Contested
Growth Analyst
bearish
28
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 50 articles, 14d)
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
55.7
Neutral
MACD Histogram
0.299
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$93.32
Resistance
$106.60
Bollinger %B
0.69
Inside Bands
Price vs Moving Averages
EMA 9
$93.89
Above
EMA 21
$92.33
Above
EMA 50
$92.40
Above
EMA 200
$105.93
Below
Fundamental Analysis
Valuation
77
Growth
18
Profitability
1
Financial Health
71
Cash Flow
37
Valuation
P/E Ratio
26.1×
P/B Ratio
3.15×
PEG Ratio
-0.49
Dividend Yield
0.03%
52W High
$137.49
52W Low
$81.97
Quality & Growth
ROE
12.5%
ROA
7.5%
Gross Margin
56.4%
Operating Margin
18.2%
Revenue Growth YoY
—
Debt / Equity
0.65
AI Fundamental Assessment
P/E ratio of 26.1 (moderate relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.1%; Gross margin of 0.6%; Current ratio of 1.39 (tight short-term liquidity); Debt-to-equity of 0.65; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (4.22); Most recent quarter missed estimates by 0.5%; 4 consecutive earnings misses; EPS growth decelerating (+15.4% -> -23.3% QoQ); Analyst estimates falling over recent quarters
Key Risks
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Bearish candlestick pattern(s) detected: Three Black Crows.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full ABT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile